Literature DB >> 18008176

Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis.

Georgios T Stathopoulos1, Taylor P Sherrill, Wei Han, Ruxana T Sadikot, Vasiliy V Polosukhin, Barbara Fingleton, Fiona E Yull, Timothy S Blackwell.   

Abstract

Nuclear factor (NF)-kappaB is frequently over-expressed in non-small cell lung cancer (NSCLC), but the exact role of this observation remains unclear. In this regard, activation of the transcription factor may govern distinct steps of NSCLC progression, such as carcinogenesis, angiogenesis, and metastasis. In these studies we attempted to dissect the effects of two proteins of the NF-kappaB pathway (p65/RelA and IkappaBetaalpha) on experimental metastasis of murine NSCLC, using a novel approach of bioluminescent detection of NF-kappaB activation in tumor cells. Stable integration of a NF-kappaBeta reporter confirmed high basal activation of the transcription factor in mouse NSCLC cells in vitro and during experimental metastasis to the lungs, like human NSCLC. In the mouse model of NSCLC metastasis, NF-kappaBeta-dependent luciferase expression served as a reliable indicator of tumor cell delivery to the lungs, establishment of metastatic tumors, and lung tumor burden. In vitro transient p65/RelA and IkappaBetaalpha gene transfer to mouse NSCLC cells resulted, respectively, in significant NF-kappaB activation and inhibition, without affecting cell growth. However, p65/RelA overexpression in NSCLC cells drastically reduced in vivo metastasis to the lungs, while overexpression of IkappaBetaalpha had no effect. In conclusion, using bioluminescent detection of NF-kappaB activation in mouse lug adenocarcinoma cells, we found a negative impact of p65/RelA on NSCLC metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18008176     DOI: 10.1007/s10585-007-9100-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  31 in total

Review 1.  Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views.

Authors:  F E Chen; G Ghosh
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

3.  Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice.

Authors:  H Nokihara; H Yanagawa; Y Nishioka; S Yano; N Mukaida; K Matsushima; S Sone
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Zhiwen Zhu; M Brett Everhart; Ioannis Kalomenidis; William E Lawson; Semra Bilaceroglu; Todd E Peterson; Daphne Mitchell; Fiona E Yull; Richard W Light; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2005-10-06       Impact factor: 6.914

5.  Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa.

Authors:  Ruxana T Sadikot; Heng Zeng; Myungsoo Joo; M Brett Everhart; Taylor P Sherrill; Bo Li; Dong-sheng Cheng; Fiona E Yull; John W Christman; Timothy S Blackwell
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.

Authors:  Ximing Tang; Diane Liu; Shishir Shishodia; Natalie Ozburn; Carmen Behrens; J Jack Lee; Waun Ki Hong; Bharat B Aggarwal; Ignacio I Wistuba
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

Review 7.  Clinical update: proteasome inhibitors in solid tumors.

Authors:  Heinz Josef Lenz
Journal:  Cancer Treat Rev       Date:  2003-05       Impact factor: 12.111

8.  Selective I kappa B kinase expression in airway epithelium generates neutrophilic lung inflammation.

Authors:  Ruxana T Sadikot; Wei Han; M Brett Everhart; Ornella Zoia; R Stokes Peebles; E Duco Jansen; Fiona E Yull; John W Christman; Timothy S Blackwell
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

9.  Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

Authors:  Dong-Myung Kim; Sun-Young Koo; Kiwan Jeon; Min Hyung Kim; Jinho Lee; Chang Yong Hong; ShinWu Jeong
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

Review 10.  The proteasome as a target for cancer therapy.

Authors:  Peter M Voorhees; E Claire Dees; Bert O'Neil; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  8 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics.

Authors:  Rong Wang; Xiao-Feng Chen; Yong-Qian Shu
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment.

Authors:  Rinat Zaynagetdinov; Taylor P Sherrill; Linda A Gleaves; Allyson G McLoed; Jamie A Saxon; Arun C Habermann; Linda Connelly; Daniel Dulek; R Stokes Peebles; Barbara Fingleton; Fiona E Yull; Georgios T Stathopoulos; Timothy S Blackwell
Journal:  Cancer Res       Date:  2015-02-17       Impact factor: 12.701

4.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

5.  Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.

Authors:  Antonia Marazioti; Ioannis Lilis; Malamati Vreka; Hara Apostolopoulou; Argyro Kalogeropoulou; Ioanna Giopanou; Georgia A Giotopoulou; Anthi C Krontira; Marianthi Iliopoulou; Nikolaos I Kanellakis; Theodora Agalioti; Anastasios D Giannou; Celestial Jones-Paris; Yoichiro Iwakura; Dimitrios Kardamakis; Timothy S Blackwell; Stavros Taraviras; Magda Spella; Georgios T Stathopoulos
Journal:  Nat Commun       Date:  2018-02-14       Impact factor: 14.919

6.  Tumor burden talks in cancer treatment with PEGylated liposomal drugs.

Authors:  Yi-Yu Lin; Hao-Wen Kao; Jia-Je Li; Jeng-Jong Hwang; Yun-Long Tseng; Wuu-Jyh Lin; Ming-Hsien Lin; Gann Ting; Hsin-Ell Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

Review 7.  Bioluminescence imaging: a shining future for cardiac regeneration.

Authors:  Santiago Roura; Carolina Gálvez-Montón; Antoni Bayes-Genis
Journal:  J Cell Mol Med       Date:  2013-02-12       Impact factor: 5.310

8.  Novel imaging approaches for small animal models of lung disease (2017 Grover Conference series).

Authors:  Isaac P Pinar; Heather D Jones
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.